Si-Han Zhang

Si-Han Zhang

Auto-generated profile, based on publicly available information

Si-Han Zhang

Department and Institute of Urology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan People's Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Heliyon
Verified
Journal Article
Open access
SZSi-Han Zhang
Si-Han Zhang
NZNa Zeng
Na Zeng
JSJian-Xuan Sun
Jian-Xuan Sun
CLChen-Qian Liu
Chen-Qian Liu
JXJin-Zhou Xu
Jin-Zhou Xu
SWShao-Gang Wang
Shao-Gang Wang
Cereblon (CRBN) has emerged as a vital E3 ubiquitin ligase for Proteolysis-targeting chimera (PROTAC) design. However, few studies focus on the physiological mechanism of CRBN, and more studies are needed to explore the influence of CRBN on tumorigenesis. This pan-cancer analysis aims to explore the prognostic and immunologic roles of CRBN, and provide new insight for CRBN into cancer treatment and PROTAC design. The TCGA database, TIMER 2.0 database, and TISIDB database were used to analyze the role of CRBN in pan-cancer. Multiple bioinformatic methods (ssGSEA, Kaplan-Meier, univariate cox regression, ESTIMATE, CIBERSORT) were applied to investigate the CRBN expression status, gene activity, prognostic values, and its correlation with immune scores, immune infiltration, immune-related functions, HALLMARKs functions, and response to immunotherapy in pan-cancer. In most cancer types, the expression and activity of CRBN in tumor groups were lower compared with normal groups. Upregulated CRBN expression may indicate a better prognosis for cancer patients. The Immune score, stromal score, and tumor purity varied greatly among different cancer types. GSEA analysis showed that high CRBN expression was correlated with the downregulation of tumor-promoting signaling pathways. The level of CRBN was associated with Tumor mutation burden (TMB), Microsatellite instability (MSI), objective response rate (ORR), and immune cell infiltration in a few cancer types. Pan-cancer analysis reveals the potential role of CRBN as a prognostic biomarker and versatile immunologic roles in different cancer types. Upregulated expression of CRBN may be beneficial to CRBN-related immunotherapy and PROTAC design.

27 September 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ZXZhi-Yu Xia
Zhi-Yu Xia
SZSi-Han Zhang
Si-Han Zhang
JSJianxuan Sun
Jianxuan Sun
Shaogang WangShaogang Wang
Shaogang Wang
QXQidong Xia
Qidong Xia
Focal therapy, a minimally invasive strategy for localized prostate cancer, has been widely employed in the targeted treatment of localized prostate cancer in recent years. We analyzed 1312 relevant papers from the last decade using Web of Science Core Collection data. Our analysis covered countries, institutions, journals, authors, keywords, and references to offer a multifaceted perspective on the development of this field. The U.S. led in publications, contributing over half of the top 10 institutions. Emberton, M from University College London was the most published and cited author. “EUROPEAN UROLOGY” was the top journal by impact factor in 2022. Analysis of references and keywords suggests the prevalence of brachytherapy-related research, while high-intensity focused ultrasound (HIFU), cryotherapy, and irreversible electroporation (IRE) are emerging as new research focuses. Consequently, more high-quality evidence is necessary to evaluate the long-term effectiveness and safety of these novel therapeutic methods.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SZSi‐Han Zhang
Si‐Han Zhang
YAYe An
Ye An
NZNa Zeng
Na Zeng
MLMei‐Cheng Liu
Mei‐Cheng Liu
JSJianxuan Sun
Jianxuan Sun
QXQidong Xia
Qidong Xia
Glutathione peroxidase 4 (GPX4) is a central guardian against ferroptosis and a critical therapeutic target for castration‐resistant prostate cancer (CRPC). However, traditional GPX4 inhibitors are often limited by irreversible covalent binding and systemic toxicity. Here, we utilized the deep learning algorithm Bindcraft to design high‐affinity de novo binders targeting GPX4. To achieve GPX4 degradation, we developed a novel modality termed binder‐degron chimera (bdC), which integrates a de novo‐designed binder with a C‐terminal combinational degron. Mechanistically, bdC recruits the CUL2‐RING E3 ubiquitin ligase complex, leading to proteasome‐mediated GPX4 degradation. To circumvent the delivery barriers inherent to macromolecular therapeutics, the bdC was encoded into a plasmid vector and encapsulated within a biomimetic nanocarrier featuring a PSMA‐targeted and CD47‐camouflaged surface (pc‐CMNP). This platform enables the in situ synthesis of bdCs specifically within prostate cancer cells, driving robust GPX4 degradation and triggering potent ferroptosis. Our work establishes a versatile framework combining deep‐learning generative binders, combinational degrons, and biomimetic nanotechnology to degrade intracellular targets and provides a novel therapeutic modality for CRPC.